Мобильная версия

Доступно журналов:

3 288

Доступно статей:

3 891 637

 

Скрыть метаданые

Автор KUMAOKA, SOICHI
Автор TAKATANI, OSAMU
Автор YOSHIDA, MINORU
Автор MIURA, SHIGETO
Автор TAKAO, TETSUTO
Автор HAMANAKA, YÜJI
Автор IZUO, MASARU
Автор OKADA, TADAKAZU
Дата выпуска 1974
dc.description A new orally active anti-estrogenic steroid, 2α,3α-epithio-5α-androstan-17β-yl 1-methoxycyclopentyl ether (10364-S) was given to 41 advanced breast cancer patients. Most patients were given a daily dose of 20 mg. The study was preliminary and not a controlled trial using an already proven androgenic steroid. The remission rate on giving this compound to advanced breast cancer was 11/41 or 26.8% and the average duration of the remission was 10.5 months.Hoarseness (8/41, 19.5%) and hirsutism (5/41, 12.2%) were relatively often seen as virilizing side effects. No unfavorable effects on the hematopoietic organs, the liver or on calcium metabolism were recognized in the study.
Формат application.pdf
Издатель Oxford University Press
Копирайт © 1974 JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Тема ORIGINALS
Название 2α,3α-Epithio-5α-androstan-17β-yl 1-Methoxycyclopentyl Ether in the Treatment of Advanced Breast Cancer —A Preliminary Clinical Trial—
Тип research-article
Electronic ISSN 1465-3621
Print ISSN 0368-2811
Журнал Japanese Journal of Clinical Oncology
Том 4
Первая страница 65
Последняя страница 68
Аффилиация KUMAOKA SOICHI; National Cancer Center Research Institute
Аффилиация TAKATANI OSAMU; National Cancer Center Hospital
Аффилиация YOSHIDA MINORU; Aichi Cancer Center Hospital
Аффилиация MIURA SHIGETO; Aichi Cancer Center Hospital
Аффилиация TAKAO TETSUTO; First Department of Surgery, Osaka University Medical School
Аффилиация HAMANAKA YÜJI; First Department of Surgery, Osaka University Medical School
Аффилиация IZUO MASARU; Department of Surgery, Gunma University, School of Medicine
Аффилиация OKADA TADAKAZU; Department of Surgery, Gunma University, School of Medicine
Выпуск 1

Скрыть метаданые